540 related articles for article (PubMed ID: 30176835)
1. N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial.
Yang C; Bosker FJ; Li J; Schoevers RA
BMC Psychiatry; 2018 Sep; 18(1):279. PubMed ID: 30176835
[TBL] [Abstract][Full Text] [Related]
2. Minocycline as adjunctive treatment for treatment-resistant depression: study protocol for a double blind, placebo-controlled, randomized trial (MINDEP2).
Husain MI; Cullen C; Umer M; Carvalho AF; Kloiber S; Meyer JH; Ortiz A; Knyahnytska Y; Husain MO; Giddens J; Diniz BS; Wang W; Young AH; Mulsant BH; Daskalakis ZJ
BMC Psychiatry; 2020 Apr; 20(1):173. PubMed ID: 32295565
[TBL] [Abstract][Full Text] [Related]
3. Prediction of nonremission to antidepressant therapy using diffusion tensor imaging.
Grieve SM; Korgaonkar MS; Gordon E; Williams LM; Rush AJ
J Clin Psychiatry; 2016 Apr; 77(4):e436-43. PubMed ID: 27137427
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial.
Berk M; Dean OM; Cotton SM; Jeavons S; Tanious M; Kohlmann K; Hewitt K; Moss K; Allwang C; Schapkaitz I; Robbins J; Cobb H; Ng F; Dodd S; Bush AI; Malhi GS
J Clin Psychiatry; 2014 Jun; 75(6):628-36. PubMed ID: 25004186
[TBL] [Abstract][Full Text] [Related]
5. Effect of Minocycline on Depressive Symptoms in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Hellmann-Regen J; Clemens V; Grözinger M; Kornhuber J; Reif A; Prvulovic D; Goya-Maldonado R; Wiltfang J; Gruber O; Schüle C; Padberg F; Ising M; Uhr M; Friede T; Huber C; Manook A; Baghai TC; Rupprecht R; Heuser I
JAMA Netw Open; 2022 Sep; 5(9):e2230367. PubMed ID: 36103181
[TBL] [Abstract][Full Text] [Related]
6. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder.
Mathew SJ; Gueorguieva R; Brandt C; Fava M; Sanacora G
Neuropsychopharmacology; 2017 Dec; 42(13):2567-2574. PubMed ID: 28553836
[TBL] [Abstract][Full Text] [Related]
7. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
Fourrier C; Sampson E; Mills NT; Baune BT
Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
[TBL] [Abstract][Full Text] [Related]
8. A Double-Blind, Randomized, Placebo-Controlled Study of Aspirin and N-Acetylcysteine as Adjunctive Treatments for Bipolar Depression.
Bauer IE; Green C; Colpo GD; Teixeira AL; Selvaraj S; Durkin K; Zunta-Soares GB; Soares JC
J Clin Psychiatry; 2018 Dec; 80(1):. PubMed ID: 30549489
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
[TBL] [Abstract][Full Text] [Related]
10. Association of thalamic hyperactivity with treatment-resistant depression and poor response in early treatment for major depression: a resting-state fMRI study using fractional amplitude of low-frequency fluctuations.
Yamamura T; Okamoto Y; Okada G; Takaishi Y; Takamura M; Mantani A; Kurata A; Otagaki Y; Yamashita H; Yamawaki S
Transl Psychiatry; 2016 Mar; 6(3):e754. PubMed ID: 26954981
[TBL] [Abstract][Full Text] [Related]
11. Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study.
Sanacora G; Johnson MR; Khan A; Atkinson SD; Riesenberg RR; Schronen JP; Burke MA; Zajecka JM; Barra L; Su HL; Posener JA; Bui KH; Quirk MC; Piser TM; Mathew SJ; Pathak S
Neuropsychopharmacology; 2017 Mar; 42(4):844-853. PubMed ID: 27681442
[TBL] [Abstract][Full Text] [Related]
12. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
Thase ME; Youakim JM; Skuban A; Hobart M; Zhang P; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
J Clin Psychiatry; 2015 Sep; 76(9):1232-40. PubMed ID: 26301771
[TBL] [Abstract][Full Text] [Related]
13. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
Barbee JG; Thompson TR; Jamhour NJ; Stewart JW; Conrad EJ; Reimherr FW; Thompson PM; Shelton RC
J Clin Psychiatry; 2011 Oct; 72(10):1405-12. PubMed ID: 21367355
[TBL] [Abstract][Full Text] [Related]
14. Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study.
Chen MH; Li CT; Lin WC; Hong CJ; Tu PC; Bai YM; Cheng CM; Su TP
Psychiatry Res; 2018 Nov; 269():207-211. PubMed ID: 30153598
[TBL] [Abstract][Full Text] [Related]
15. Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial.
McAllister-Williams RH; Anderson IM; Finkelmeyer A; Gallagher P; Grunze HC; Haddad PM; Hughes T; Lloyd AJ; Mamasoula C; McColl E; Pearce S; Siddiqi N; Sinha BN; Steen N; Wainwright J; Winter FH; Ferrier IN; Watson S;
Lancet Psychiatry; 2016 Feb; 3(2):117-27. PubMed ID: 26727041
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.
Thase ME; Youakim JM; Skuban A; Hobart M; Augustine C; Zhang P; McQuade RD; Carson WH; Nyilas M; Sanchez R; Eriksson H
J Clin Psychiatry; 2015 Sep; 76(9):1224-31. PubMed ID: 26301701
[TBL] [Abstract][Full Text] [Related]
17. The Post-Anaesthesia N-acetylcysteine Cognitive Evaluation (PANACEA) trial: study protocol for a randomised controlled trial.
Skvarc DR; Dean OM; Byrne LK; Gray LJ; Ives K; Lane SE; Lewis M; Osborne C; Page R; Stupart D; Turner A; Berk M; Marriott AJ
Trials; 2016 Aug; 17():395. PubMed ID: 27502769
[TBL] [Abstract][Full Text] [Related]
18. Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial.
Murrough JW; Wade E; Sayed S; Ahle G; Kiraly DD; Welch A; Collins KA; Soleimani L; Iosifescu DV; Charney DS
J Affect Disord; 2017 Aug; 218():277-283. PubMed ID: 28478356
[TBL] [Abstract][Full Text] [Related]
19. N-acetylcysteine as an adjunctive treatment for bipolar depression and major depressive disorder: a systematic review and meta-analysis of double-blind, randomized placebo-controlled trials.
Kishi T; Miyake N; Okuya M; Sakuma K; Iwata N
Psychopharmacology (Berl); 2020 Nov; 237(11):3481-3487. PubMed ID: 32767039
[TBL] [Abstract][Full Text] [Related]
20. Interpersonal psychotherapy as add-on for treatment-resistant depression: A pragmatic randomized controlled trial.
Souza LH; Salum GA; Mosqueiro BP; Caldieraro MA; Guerra TA; Fleck MP
J Affect Disord; 2016 Mar; 193():373-80. PubMed ID: 26799332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
